A
ACRS
Aclaris Therapeutics, Inc. Common Stock
$3.38
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Aclaris Therapeutics, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$0.59
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.17
Nov 11
Posts
No posts about ACRS yet.
About Aclaris Therapeutics, Inc. Common Stock
Aclaris Therapeutics is a US biotech company that develops drugs for immune-related diseases, such as skin and joint conditions. It has no approved product on the market, so it earns almost no sales. It pays for research mainly with cash raised from investors, plus small amounts of collaboration and royalty income.